EMA Application withdrawn: Vorinostat MSD (vorinostat) — Merck Sharp Dohme Limited

View source ↗

Summary

EMA withdrew the application for vorinostat (MSD) by Merck Sharp & Dohme Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma T-cell Cutaneous

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Status: Application withdrawn. Therapeutic area: Lymphoma, T-Cell, Cutaneous. MAH: Merck Sharp Dohme Limited. Decision date: 31/12/2009